to begin with and be bloody-minded about continuing this specific interest. You should always enjoy biology, even when some aspects of doing research are tedious or even unsuccessful. If you don't enjoy what you are doing, then you might as well be in business and be paid well to do boring things! Beyond that it is a matter of personal style; my advice depends upon where you are on the personality gradient between risk-adverse and risk-prone, and how comfortable you are with the unpredictable.
At one extreme, if you are (like me) more risk-prone, you should be extremely exploratory, daring, and original in the scientific questions you ask and do research on. Do 'interesting' science rather than 'important' science. This is more likely to yield significant new discoveries because few people have addressed supposedly 'unimportant' questions. The history of science suggests that almost no major discoveries were done because that research topic was 'important' at that time. There is a bigger risk to your career in going for interesting science for three reasons: you might get into an intellectual cul-de-sac, so you need to learn how to recognize dead ends; it is much harder to get funding for really original or 'unimportant' science; you need to have thorough knowledge which cuts across several scientific fields, which takes longer and requires more effort. You will also have to learn how to recognize completely new phenomena. Don't get caught in intellectual ruts caused by excessive reading of the literature, but do be careful to ensure that you give all credit to all published work. Let natural phenomena be your guide rather than the literature if you want to make really new discoveries.
At the other extreme, if you are risk-adverse, then stick to 'important' and applied science or technology, it is far easier because questions are well-defined and funding is easy, and its easy to churn out papers making tiny advances, so your career will advance quickly. But the risk is that you won't make any significant contribution to science and your name will be forgotten after you go into administration because tiny advances are not satisfying, or retire, rich. As you can see, where you sit on the gradient is a matter of taste and style, but don't forget your original goals! What do you think of the worldwide trend in research councils and foundations towards more and more applied research at the expense of 'pure' research? I am worried by this trend. It is presumably driven by the fact that research councils and foundations have to justify spending money to their governments and boards, and it is difficult to sustain funding if it seems 'unimportant' or even 'useless'. Very few people controlling research funding realize that breakthroughs in science are like a tree giving off thousands of seeds of which only a few germinate. As a result, the people in councils have to favor 'important' science, and researchers have to stretch descriptions of basic research to sound as though it has significant applied implications. This is terrible, for two reasons. First it inhibits genuine exploratory ('blue sky') research, hence greatly reduces the probability of genuinely new discoveries and concepts. Second, and positively dangerous, the constant exaggerated description of all research projects having supposedly significant applied outcomes is constantly raising the expectations of the public. As this gets worse and worse expectations rise and failures become more frequent, and public confidence in science declines. This is the classical problem of short-term gains at the expense of long-term survival. Pretending all science has immediate beneficial applications results in long term destruction of support for and interest in science. Right now we are just depending upon sheer numbers of researchers stumbling on new phenomena in a social atmosphere of rapidly declining confidence in science because we are constantly raising expectations. Somebody needs to write a popular book about the cultural/social environment that has favored major scientific breakthroughs in the past, and how this needs to be encouraged. We risk the long-term survival of science by not letting the public know how science really proceeds.
If you were to start over, would you do it again? Yes! I really enjoy doing science, satisfying my curiosity and discovering the unexpected. 
Oncogene addiction Jeffrey Settleman
What is oncogene addiction? The term 'oncogene addiction' was first coined by Bernard Weinstein to describe the dependency of certain tumor cells on a single activated oncogenic protein or pathway to maintain their malignant properties, despite the likely accumulation of multiple gainand loss-of-function mutations that contribute to tumorigenicity. The term has been reinforced by several reported findings in animal tumor models in which oncogene-driven tumors, either generated as xenografts or through the use of genetically engineered models, have been found to undergo regression, associated with proliferative arrest, apoptosis, and/or differentiation following the acute inhibition of oncoprotein function.
Should this surprise anyone?
Many scientists in the oncology research community view the oncogene addiction concept as 'trivial', suggesting that it is obvious that a mutation that contributes causally to tumorigenesis would be required for cancer cells to maintain their malignant phenotype. However, this is almost certainly not universally true. Thus, cancer cells frequently undergo genome instability caused by disruption of normal DNA repair and replication mechanisms, and this can certainly result from mutational events that affect, for example, genes encoding components of the DNA damage response machinery. Such mutational events lead to the accumulation of additional potentially oncogenic mutations, but are clearly exerting their actions via a 'hit and run' mechanism. Similarly, one could imagine oncogenic events that play a role in the initiation of tumorigenesis, for example, by expanding a tumor stem cell population, but that are not necessarily required to maintain tumorigenicity once a tumor has sufficiently 'matured'.
What is the 'oncogenic shock' theory?
Oncogenic shock is a signaling mechanism that has been proposed
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to explain the death of oncogeneaddicted cancer cells upon inhibition of the oncoprotein to which they are addicted. Based on studies with cell line culture models, oncogenic shock refers to an acute imbalance in the output of pro-apoptotic and prosurvival signaling from an oncogenic kinase (such as EGFR or BCR-ABL) following kinase inhibition by drug exposure. Such kinases are believed to transduce both short-lived pro-survival signals that are rapidly attenuated upon kinase inhibition, and longer-lived pro-apoptotic mechanisms that decay more slowly following kinase inhibition. In the absence of drug treatment, the pro-apoptotic signals are held in check by pro-survival signals, thereby promoting cancer cell survival. However, upon drug-mediated kinase inhibition, the differential decay rate of these two types of signals reverses the balance, leading to excessive proapoptotic signaling and consequent tumor cell death. While this is difficult to demonstrate in a clinical context, recent studies in mouse tumor models have yielded findings that support the oncogenic shock mechanism in vivo.
Is oncogene addiction clinically significant? The phenomenon of oncogene addiction, irrespective of its mechanistic underpinnings, is widely recognized as a likely contributor to the impressive clinical activity that has recently been observed following treatment with so-called 'rationally-targeted' agents. The clinical responses to such single agents in patients with metastatic disease that was largely refractory to standard chemotherapies is nothing short of remarkable. For example, a high percentage of EGFR mutant non-small cell lung cancers, BRAF mutant melanomas, and ALK mutated lung tumors respond to drugs that selectively inhibit these mutationally activated kinases. Similar clinical observations in BCR-ABL translocated cases of chronic myelogenous leukemia, PDGF receptor and c-KIT mutant gastrointestinal tumors, and JAK-mutant myeloproliferative disorders provide additional examples of genotype-associated drug responses seemingly associated with oncogene addiction. Such findings have prompted great interest in exploring additional clinical opportunities in which oncogene addiction provides a rationale for matching patients with the most effective drug therapies. Additional examples of mutationally activated targets that are currently being examined in this regard are PI-3 kinase, AKT, MEK, FGF receptor, and MET. Such mutationally activated oncogenes have been referred to as the 'Achilles' heels' of cancer.
Is this only relevant for kinases?
The most clinically validated examples of oncogene addiction have been associated with mutationally activated kinases. However, cell culture and animal tumor studies have demonstrated a likely role for oncogene addiction for other important cancer genes, such as c-MYC and RAS. Indeed, the first experimental demonstrations of oncogene addiction were in the setting of MYC-or RASdriven mouse tumors, in which acute inhibition of expression of these inducible oncogenes led to rapid tumor regression. Thus, it is possible that a variety of oncogenes, beyond the activated kinases, are associated with oncogene addiction. However, the development of drugs that inhibit the function of such proteins (such as MYC and RAS) can be substantially more challenging than it has been for the kinases.
How about non-oncogene addiction?
The term 'non-oncogene addiction' was first coined by Steve Elledge in the context of findings by Susan Lindquist's group that revealed a requirement for heat-shock factor 1 (HSF1) to maintain malignancy in tumor cells experiencing various forms of stress. HSF1 is not mutated in cancer, but its requirement in cancer cells is apparently revealed in specific physiological contexts associated with tumors, such as hypoxia. If HSF1 was found to be a tractable drug target, such findings could pave the way to a drug-targeting strategy associated with non-oncogene addiction. Other examples of non-oncogene addiction are beginning to accumulate in the published literature.
Is non-oncogene addiction clinically relevant? One of the best examples of non-oncogene addiction relates to the so-called 'synthetic lethality' associated with drugs that inhibit poly(ADP ribose) polymerase (PARP). Although PARP is not mutationally activated in cancer, PARP inhibition appears to be selectively effective in tumors harboring loss-of-function alleles of the tumor suppressors BRCA1 and BRCA2. In those contexts, cancer cells suffering a deficiency in DNA repair as a consequence of losing BRCA function become vulnerable to PARP inhibition, which further contributes to DNA damage that cannot be repaired in 'BRCA-less' tumors, leading to tumor cell death.
And what about 'lineage addiction'?
Lineage addiction refers to yet another form of non-oncogene addiction in which cell-lineage-specific factors may be required to maintain tumor cell identity and possibly function, thereby defining a potential therapeutic targeting strategy. Among the best examples defined thus far is the demonstration that some melanomas remain dependent for their survival on the maintenance of elevated expression of the micropthalmiaassociated transcription factor (MITF) -which does not undergo mutation in melanomas.
How will we find more examples of oncogene and non-oncogene addiction? Now that we have proofof-concept that targeting oncogene addiction states can yield clinical efficacy, there has been a substantial increase in the effort to find additional examples. Much of this analysis has been in the form of RNAi-based screens, owing to the power of this technology to functionally interrogate the human genome in the context of cell-based assays. Consequently, we are beginning to see the emergence of a large number of candidate therapeutic targets that will require further validation to be considered viable for drug discovery.
